RxDoctor Payments Data

Ashley Brandon, MD

Urology · Burlington, NCNPI 1790912574

Payments from drug & device makers

$3,569in general payments, 2019–2025

Across 189 payments — averaging $18.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$509
  • Pfizer$363
  • Coloplast$297
  • Johnson & Johnson$296
  • Neotract Inc.$262
  • Antares Pharma, Inc.$230
  • plus $2K from 28 others

What the payments were for

  • Food & beverage$3,31293%
  • Education$2577%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,569 in reported general payments places this provider in the 55th percentile of 434 urology providers in North Carolina.

See all urology providers in North Carolina

Medicare billing

Part B allowed, 2024
$103,180
Medicare patients
257
Services billed
1,217

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ErleadaApalutamide14$204,602
OrgovyxRelugolix48$130,257
MyrbetriqMirabegron99$61,269
GemtesaVibegron78$58,987
PremarinEstrogens, Conjugated11$4,784
Tamsulosin Hcl352$4,659
Estradiol55$3,812
Finasteride205$3,307
Oxybutynin Chloride ErOxybutynin Chloride57$1,575
Trospium Chloride28$1,208
Potassium Citrate ErPotassium Citrate20$1,144
Testosterone Cypionate13$694
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst41$532
Alfuzosin Hcl ErAlfuzosin Hcl17$394
Solifenacin Succinate15$376

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonErleada$296$204,60214 claims
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$45$189,244126 claims
Astellas Pharma US IncMyrbetriq$509$61,26999 claims
PfizerPremarin$363$4,78411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 434 urology providers in North Carolina.

Other urology in Burlington

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →